This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Senex Biotechnology


Company/Organization Description or Summary

Senex Biotechnology is a drug discovery and development company focused on preventing the transcriptional reprogramming that allows cancer cells to develop resistance to therapeutics. Senex’s lead program targets CDK8/19 Mediator Kinase, a protein that facilitates transcriptional reprogramming. This process alters gene expression and is required by cancer cells to adapt to adversarial conditions; such adaptation leads to cancer drug resistance and metastasis. Senex scientists discovered the role of CDK8/19 Mediator Kinase in multiple oncology indications. Senex is developing highly selective small-molecule inhibitors of this protein for the treatment of presently incurable types of prostate cancer, drug resistant breast cancer and leukemia. We are also investigating the utility of these inhibitors for different cancers in combination with other therapeutics, as well as for inflammation, cardiovascular and other diseases. Senex has broad patent protection for CDK8/19 Mediator Kinase inhibitors, with new composition of matter protection on our clinical candidate.